Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have been assigned an average rating of “Moderate Buy” from the four analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $3.3333.

Several brokerages have commented on CGTX. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Wednesday, June 24th. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Cognition Therapeutics in a report on Monday, June 22nd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Essex Financial Services Inc. acquired a new stake in Cognition Therapeutics in the 4th quarter valued at approximately $27,000. Gamco Investors INC. ET AL acquired a new position in Cognition Therapeutics during the 3rd quarter worth approximately $27,000. Private Management Group Inc. acquired a new position in Cognition Therapeutics during the 3rd quarter worth approximately $32,000. Marshall Wace LLP bought a new position in shares of Cognition Therapeutics during the 4th quarter worth approximately $37,000. Finally, Raymond James Financial Inc. grew its stake in shares of Cognition Therapeutics by 34.7% during the 3rd quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock worth $40,000 after acquiring an additional 7,641 shares in the last quarter. 43.35% of the stock is owned by institutional investors and hedge funds.

Cognition Therapeutics Trading Up 1.8%

Shares of CGTX stock traded up $0.02 on Thursday, hitting $0.92. The stock had a trading volume of 59,100 shares, compared to its average volume of 1,220,692. The firm has a market cap of $82.07 million, a P/E ratio of -3.80 and a beta of 1.75. Cognition Therapeutics has a twelve month low of $0.55 and a twelve month high of $3.83. The company has a fifty day moving average price of $1.16 and a two-hundred day moving average price of $1.14.

Cognition Therapeutics (NASDAQ:CGTX) last posted its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect that Cognition Therapeutics will post -0.32 earnings per share for the current year.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.